Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-04-05
2011-04-05
Chernyshev, Olga N (Department: 1649)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007210, C435S007800, C435S007920
Reexamination Certificate
active
07919262
ABSTRACT:
The present disclosure is directed to methods for treatment and prevention of disease states characterized by a decreased 14-3-3 polypeptide expression or activity. In one embodiment, the present disclosure provides methods for the treatment and/or prevention of Parkinson's disease, neurodegeneration and/or diseases characterized, at least in part, by neurodegeneration, by increasing a 14-3-3 polypeptide activity.
REFERENCES:
patent: 5856445 (1999-01-01), Korsmeyer
patent: 5998149 (1999-12-01), Hsich et al.
patent: 7001720 (2006-02-01), Polymeropoulous et al.
patent: 2005/0009094 (2005-01-01), Mueller et al.
Kevin Welch & Junying Yuan, Releasing the Nerve Cell Killers, Nature Medicine, vol. 8 No. 6, Nature Publishing Group, Jun. 2002.
Jin Xu, Shyan-Yuan Kao, Frank J.S. Lee Weihong Song, Lee-Way Jin & Bruce Yankner, Dopamine-dependant neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease, Nature Medicine, vol. 8 No. 6, Nature Publishing Group, Jun. 2002.
Nahum Meller, Yun-Cai Liu, Tassie L. Collins, Nathalie Bonnefoy-Berard, Gottfried Baier, Noah Isakov and Amnon Altman, Direct Interaction Between Protein Kinase Cθ (PKCθ) and 14-3- 3τ in T cells: 14-3-3 Overexpression Results in Inhibition of PKC θ Translocation and Function†, Molecular and Cell. Biology, Oct. 1996, p. 5782-5791, vol. 16, No. 10, American Society for Microbiology, 1996.
John A. Thorson,1 Lily W. K. Yu,1 Alice L. Hsu,1 Neng-Yao Shih,1 Paul R. Graves,2 J. William Tanner,1 Paul M. Allen,1 Helen Piwnica-Worms,2,3 and Andrey S. Shaw1,* , 14-3-3 Proteins Are Required for Maintenance of Raf-1 Phosphorylation and Kinase Activity, Molecular and Cell. Biology, Sep. 1998, p. 5229-5238, vol. 18, No. 9, American Society for Microbiology, 1998.
Gary R. Fanger, Christian Widmann, Amy C. Porter , Sue Sather, Gary L. Johnson, and Richard R. Vaillancourt, 14-3-3 Proteins Interact with Specific MEK Kinases, The Journal of Biological Chemistry, vol. 273, Issue 6, 3476-3483, Feb. 6, 1998.
S. C. Masters, R. R. Subramanian, A. Truong, H. Yang, K. Fujii, H. Zhang, H. Fu, Survival-promoting functions of 14-3-3 proteins. Biochemical Society Transactions (2002) vol. 30, part 4.
Masaya Nomura, Shigeomi Shimizu, Tomoyasu Sugiyama, Masashi Narita, Toshinori Ito, Hikaru Matsuda, and Yoshihide Tsujimoto; 14-3-3 Interacts Directly with and Negatively Regulates Pro-apoptotic Bax*, The Journal of Biological Chemistry, vol. 278, Issue 3, 2058-2065, Jan. 17, 2003.
Michele K. Dougherty and Deborah K. Morrison, Unlocking the code of 14-3-3, Journal of Cell Science 117, 1875-1884 (2004), Published by The Company of Biologists 2004.
Pierre-Olivier Fernagut and Marie-Francoise Chesselet , Alpha-synuclein and transgenic mouse models, Neurobiology of Disease, vol. 17, Issue 2, Nov. 2004, pp. 123-130.
Elizabeth J. Ryu, James M. Angelastro, and Lloyd A. Greene, Analysis of gene expression changes in a cellular model of Parkinson disease, Neurobiology of Disease, vol. 18, Issue 1, Feb. 2005, pp. 54-74.
William Lin, B.A., Un Jung Kang, MD, Neuroprotective Therapy in Parkinson's Disease: Current Status and New Directions from Experimental and Genetic Clues, Journal of Clinical Neurology, vol. 1, Oct. 2005.
Shigeto Sato, Tomoki Chiba, Eri Sakata, Koichi Kato, Yoshikuni Mizuno, Nobutaka Hattori and Keiji Tanaka, 14-3-3 is a novel regulator of parkin ubiquitin ligase, The EMBO Journal (2006) 25, 211-221, doi:10.1038/sj.emboj.7600774, Published online Aug. 11, 2005.
Luca Brunelli, Katarzyna A. Cieslik, Joseph L. Alcorn, Matteo Vatta, Antonio Baldini, Peroxisome Proliferator-Activated Receptor-δ Upregulates 14-3-3 in Human Endothelial Cells via CCAAT/Enhancer Binding Protein-β, Circulation Research. 2007;100:e59-e71, American Heart Association, Inc. 2007.
Standaert David G.
Yacoubian Talene Alene
Bradley Arant Boult & Cummings LLP
Chernyshev Olga N
The UAB Research Foundation
LandOfFree
14-3-3 proteins for diagnosis of Parkinson's disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 14-3-3 proteins for diagnosis of Parkinson's disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 14-3-3 proteins for diagnosis of Parkinson's disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2722548